106 results about "Aortic valve" patented technology

The invention discloses an aortic valve function evaluation device which comprises a processor and a memory, and the memory stores programs or instructions capable of running on the processor. When the program or the instruction is executed by the processor, the following steps are realized: acquiring a first echocardiogram of a target object corresponding to a final systole and a second echocardiogram of a target object corresponding to a final diastole in a cardiac cycle, and acquiring medical record data of the target object; determining a first mask pattern corresponding to the first echocardiogram and a second mask pattern corresponding to the second echocardiogram according to the first echocardiogram, the second echocardiogram and an aortic valve segmentation model; determining an aortic valve morphological index of the target object according to the first mask pattern and the second mask pattern; determining aortic valve functional indexes of the target object according to the medical record data of the target object; and determining and outputting an aortic valve function evaluation result of the target object according to the first mask pattern, the second mask pattern, the aortic valve morphological index and the aortic valve functional index.

The application discloses a guide wire transvalvular guide device for aortic valve replacement surgery, comprising: an inner tube providing a guide wire channel, the distal end of the inner tube being a guide wire outlet; the multiple far-end bags are isolated from one another, and the far-end bags are sequentially arranged on the periphery of the inner tube in the circumferential direction; the outer tube is slidably arranged on the periphery of the inner tube in a sleeving mode, and the far-end bag can be stored to adapt to interventional delivery; the inner tube and the outer tube are controlled by the control handle, a plurality of near-end bags are arranged in the control handle, and the near-end bags and the far-end bags are communicated in a one-to-one correspondence mode and are loaded with fluid; the driving sleeve and the rotating sleeve are arranged on the peripheries of all the near-end bags in a sleeving mode, an extrusion part protruding inwards in the radial direction is arranged in the driving sleeve, and when the driving sleeve rotates, the extrusion part acts on the near-end bags and enables the far-end bag exposed out of the outer tube to deform so as to change the pointing direction of the guide wire outlet. Through mutual linkage of the far-end bag and the near-end bag, the guide wire outlet direction is accurately adjusted, the interventional delivery and release performance is optimized, and the operation efficiency and convenience are improved.

A catheter assembly for retaining a prosthetic valve as the prosthetic valve is guided to a point of delivery within a patient is provided with radioscopic markers. The markers are distributed within the catheter assembly such that an observer may discern a rotational orientation of the assembly from a radioscopic image of the assembly within the patient. Delivery of the prosthetic valve may include aligning the markers with the commissures of the prosthetic valve and radioscopic observation of the location or movement of the markers to rotationally align the prosthetic valve with a native valve within the patient, such as by aligning the commissures of the prosthetic valve with the commissures of the native valve.

An adjustable structure, comprising: a variable catheter (101) and an adjustment tube (103), wherein the variable catheter (101) is provided with a protrudable portion (102), which comprises an outer protruding side (1023) and an inner protruding side (1024), the height by which the outer protruding side (1023) can protrude being greater than the height by which the inner protruding side (1024) can protrude. A guidewire-assisted transvalvular device (100) comprising an adjustable structure. The lateral position of the distal end of the variable catheter (101) is controlled by means of adjusting the protruding height, so that the guidewire-assisted transvalvular device (100) can be stably fixed at the aortic valve orifice, making it convenient for a guidewire located inside the adjustment tube (103) to smoothly cross the aortic valve orifice so as to prepare for a subsequent TAVR procedure.

The disclosure provides a subclinical valve leaflet thrombosis auxiliary identification method, system and signal acquisition device after transcatheter aortic valve replacement, belonging to the technical field of heart information acquisition and identification. The subclinical valve leaflet thrombosis auxiliary identification method is used for auxiliary diagnosis of subclinical valve leaflet thrombosis after transcatheter aortic valve replacement, comprising: collecting a heart sound signal, processing the heart sound signal, obtaining preset parameters of the heart sound signal, and the preset parameters at least including time, frequency and energy; determining a systolic period according to the heart sound signal; identifying the highest energy point in the characteristic interval of the systolic period; obtaining the characteristic frequency corresponding to the highest energy point, and judging whether the characteristic frequency is greater than the threshold frequency, if yes, marking the heart sound signal as an abnormal heart sound signal caused by subclinical valve leaflet thrombosis; if not, marking the heart sound signal as a normal heart sound signal. The method solves the problem that the subclinical valve leaflet thrombosis detection mainly uses multi-dimensional computed tomography, which leads to limited scope of application.

The invention provides a delivery system. The delivery system comprises a sheath tube, a sheath core and a sheath core connector, the sheath core is nested in an inner cavity of the sheath tube, and the sheath core comprises a sheath core main body tube and two reference wires which are symmetrical about the center of the sheath core; the sheath core connector is arranged on the sheath core in a sleeving mode and comprises a fixing part at the near end and a rotating part at the far end, the fixing part is fixedly arranged on the sheath core body tube, and the rotating part can rotate relative to the sheath core. According to the conveying system, before the valve prosthesis is loaded into the sheathing canal, the sheath core connector rotating part can be rotated to circumferentially adjust the valve prosthesis to the optimal position, it is ensured that after the valve prosthesis is conveyed to the designated position, the connection part of the valve prosthesis is aligned with connection of a native aortic valve, and the release accuracy is improved.

The application provides a rotating type artificial mechanical heart valve, and belongs to the technical field of heart valves, and comprises: a valve ring; a valve leaflet group, which is rotationally arranged in the valve ring; when the valve leaflet group is in an open state, a spiral channel is formed in the valve ring; and when the valve leaflet group is in a closed state, the valve leaflet group limits blood flow through the valve ring; the rotating type artificial mechanical heart valve of the application forms a spiral channel with the same rotation direction as the blood rotation flow state when the valve leaflet group is in the open state; the spiral channel is arranged to effectively rotate the blood flow, generate corresponding spiral flow state, and the rotation of the outlet blood flow is beneficial to the full flow and development of the blood flow in the aorta, reduces the turbulence, stagnation area and damage to the normal rotation flow state in the aorta, and the heart valve provided by the application has excellent hemodynamic characteristics and can effectively inhibit the aortic dilation complication caused by aortic valve replacement.

This invention discloses a method for predicting sudden cardiac death based on forensic autopsy data using machine learning and its forensic applications, belonging to the fields of machine learning, statistics, and forensic identification. This invention provides a method for screening independent predictors of forensic diagnosis of sudden cardiac death using LASSO regression and logistic regression. Using 10-fold cross-validation, the method selects the minimum lambda(λ) to identify 14 risk factors. Logistic regression ultimately identifies 9 independent predictors, including age, heart weight, left ventricular wall thickness, right ventricular wall thickness, interventricular septum thickness, aortic valve circumference, mitral valve circumference, liver weight, and left kidney weight. A nomogram and a web-based calculator are constructed for predicting sudden cardiac death in forensic practice, thereby determining sudden cardiac death using objective indicators. This method has not been reported worldwide.

The present invention relates to products and compositions and their uses. In particular, the invention relates to nucleic acid products that interfere with the expression of the LPA gene or inhibit its expression, preferably for use as a treatment / treatment, prevention or reduction of the risk of (an individual) suffering from cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome associated with elevated levels of Lp(a) particles.

Prosthetic valves are provided, e.g., for replacing a mitral or aortic valve of a patient, that includes an annular valve body including an inlet end, an outlet end, and one or more valve members for selectively opening and closing a passage between the inlet and outlet ends, a sewing cuff attached around an outer perimeter of the valve body, and a flexible skirt removably attached around the outer perimeter adjacent the sewing cuff. The prosthetic valve may be introduced into a patient's body, positioned adjacent a valve annulus, and the sewing cuff may be secured around a perimeter of the valve annulus. The skirt may be secured to tissue adjacent the valve annulus to further seal the prosthetic valve around the valve annulus, or the skirt may be removed from the valve body, e.g., if the annulus is sufficiently sealed by the sewing cuff.

A method of delivering a transcutaneous dual valve replacement (TDVR) device to a patient includes the steps of advancing a guide catheter into the heart of the patient, advancing a support wire through the guide catheter and across the mitral valve of the heart of the patient, removing the guide catheter, advancing a delivery sheath over the support wire and across both the aortic valve and the mitral valve of the heart of the patient, advancing the TDVR device over the support wire and through the delivery sheath, removing the delivery sheath, expanding a first segment of the TDVR device in the mitral valve and a second segment of the TDVR device in the aortic valve, and removing the support wire.

This invention discloses a novel valve stent and artificial heart valve, belonging to the field of medical device technology. The valve stent has a hollow, symmetrical, mesh-like tubular structure, with a first layer of hexagonal mesh groups, a second layer of polygonal mesh groups, and a third layer of polygonal mesh groups arranged sequentially from the outflow end to the inflow end. The stent has a small overall mesh count and symmetrical structure, resulting in uniform deformation during compression and expansion. It exhibits excellent radial support and minimal expansion rebound, significantly reducing the risk of paravalvular leakage. While maintaining radial support, this invention can reduce the stent strut width to 0.2–0.4 mm, and the minimum outer diameter of the valve after compression can reach 2.5–4.5 mm. Simultaneously, the overall length change during stent compression and expansion is minimal, greatly improving the smoothness of vascular delivery and the accuracy of valve implantation positioning. This meets the clinical needs of transcatheter aortic valve replacement surgery, enhancing the safety and effectiveness of artificial heart valve implantation.

The application belongs to the technical field of medical devices, and relates to a delivery system for a prosthetic valve, which comprises a guide wire, an ultrasonic probe and a processing module. The guide wire is used to build a delivery channel for a prosthetic valve to be delivered, and the end of the guide wire is provided with a guide wire head. The ultrasonic probe is arranged on the guide wire head, and is used to emit ultrasonic signals to the aorta and receive ultrasonic echo signals. The processing module is used to receive and respond to the ultrasonic echo signals, determine an aortic valve opening area according to the ultrasonic echo signals, output a first control instruction according to the aortic valve opening area and a current position of the guide wire head obtained in advance, and drive the guide wire head to move to the aortic valve opening area. The application reduces the difficulty of over-valve operation, shortens the operation time, avoids other surgical risks caused by long operation time, and has high safety.

The disclosure relates to heart valve prostheses with the reduced need of pacemaker implantation and / or improved means for positioning the replacement heart valve. A heart valve prosthesis is provided with a stent and at least one locator. The locator has an adapted design for positioning within a cusp of the native aortic valve for implantation at the native heart valve site. Placement of the locators within the cusps preferably prevents movement from the native heart valve site post-implantation, including proximal movement of the prosthesis into the left ventricle.

The application provides a catheter pump placement position judgment method, system, electronic equipment and medium. First, the catheter pump is started and controlled to operate at a predetermined rotating speed. Then, a current signal of a motor of the catheter pump and a pressure signal of a pressure sensor of the catheter pump within a predetermined time are acquired. The position of a blood outlet and a blood inlet of the catheter pump relative to an aortic valve can be judged based on the acquired current signal and pressure signal. The application only uses the data of the motor and the pressure sensor of the catheter pump, does not need to introduce other invasive measuring equipment, is beneficial to the doctor to quickly and accurately judge the placement position of the catheter pump, reduces the risk that the catheter pump cannot provide effective blood flow dynamics support due to the incorrect placement position of the catheter pump, and can directly and accurately reflect the state of the heart, greatly improving the safety of the operation.

The invention discloses a pulmonary arterial hypertension recognition device and method based on multiple paths of electrocardio heart sound signals, and relates to the technical field of biomedicine, and the method comprises the steps: limiting an aortic valve closing candidate peak and a drop point of a pulmonary valve closing candidate peak in a time interval between a main peak anchor point time boundary of a double-anchoring split fragment set and an electrocardio fragment key turning point; adjacent beat backtracking replacement and multi-channel consistent voting retention are performed on candidate peaks of cross-beat hopping, and a physiological consistent split fragment set is generated; and according to the physiological consistency split fragment set, converging split sequences of multiple paths of heart sounds, and carrying out beat-level splicing and in-window consistency closing on the split sequences and right heart load related form entries of multiple paths of electrocardio, so as to generate a pulmonary arterial hypertension recognition and diagnosis set. According to the method, high-precision synchronization of multiple paths of electrocardiogram and heart sound signals is realized, equipment difference and noise interference are eliminated, the reliability of feature extraction is guaranteed, and the pulmonary arterial hypertension recognition stability is improved.

The application discloses a kind of left ventricular mass regression risk prediction method after transcatheter aortic valve replacement, belong to postoperative prediction technical field, its purpose is to solve the technical problem that there is no technology in prior art to effectively predict the risk of left ventricular reverse remodeling after mass regression after transcatheter aortic valve replacement.It includes the following steps: obtaining preoperative heart CT image to be predicted;According to the preoperative heart CT image to be predicted, the image-based parameters of epicardial fat are extracted;According to the extracted image-based parameters, calculate the image-based score;According to the image-based score, calculate the risk probability of left ventricular mass regression after transcatheter aortic valve replacement.Using innovative algorithm, the risk value of left ventricular mass regression can be calculated and predicted, and the risk of left ventricular reverse remodeling after mass regression after transcatheter aortic valve replacement can be effectively predicted.

This invention relates to compounds, pharmaceutical compositions, combination formulations, and dosage regimens for treating, inhibiting the progression of, and preventing cardiovascular calcification, particularly coronary artery calcification, aortic calcification, and aortic valve calcification, comprising myo-inositol hexaphosphate. In one particular aspect, this disclosure provides dosage regimens for treating, inhibiting the progression of, or preventing cardiovascular calcification, comprising administering approximately 200 mg to approximately 700 mg of myo-inositol hexaphosphate per dose.

The invention belongs to the technical field of aortic valve and ascending aorta pathological assessment, and particularly relates to an aortic valve and ascending aorta in-vitro assessment method, system and equipment and a medium, which are applied to a test system based on an aortic valve and ascending aorta entity model customized by a patient. The method comprises the following steps: in a simulation test process of an aortic valve and ascending aorta entity model of a patient, acquiring a PIV velocity field, a multi-point pressure time sequence and a flow time sequence through a flow meter, a pressure sensor and a high-frequency camera which are pre-arranged in the aortic valve and ascending aorta entity model; calculating a corresponding time domain-frequency domain mechanical index according to the time domain-frequency domain mechanical index; calculating a corresponding period consistency index according to the test period of the simulation test; and integrating all the time domain-frequency domain mechanical indexes and the period consistency indexes, and evaluating the conditions of the aortic valve and the ascending aorta of the patient according to the time domain-frequency domain mechanical indexes and the period consistency indexes, so as to serve as a basis for preoperative decision making and instrument evaluation.

Systems, devices and methods are provided for supporting cardiac function. A device comprises a catheter having a shaft with a distal end portion configured for advancing through an aortic valve to a left ventricle of a patient and an impeller coupled to the distal end portion of the catheter. One or more inlets are positioned distal of the impeller and coupled to an internal lumen within the catheter to draw blood from the left ventricle through the inlets and into the internal lumen. One or more outlets positioned proximal of the impeller and coupled to the internal lumen to pump the blood through the outlets and into the aorta. The device further includes an extracorporeal motor coupled to a proximal end portion of the catheter and a drive member extending through the catheter shaft and coupling the impeller with the motor to rotate the impeller. The motor may comprise a non-contact motor that generates a magnetic field to rotate the drive member.

Methods and systems are provided for assessing an area of interest in the circulatory system of a subject. The method comprises: obtaining (210) a temporal sequence of ultrasound image frames of the area of interest; obtaining (220, 320) one or more trained models; inputting (250, 350) the temporal sequence of ultrasound image frames into the one or more trained models; and analysing (260, 360) the temporal sequence of ultrasound image frames, using the one or more trained models, to produce output data characterising a condition of the area of interest, wherein the output data characterises an extent of atherosclerosis or calcification of the area of interest, and wherein the area of interest is the aortic valve. An associated training method for training the one or more models is also provided.

The application discloses an interventional system with interception function, which comprises an interventional delivery system and an artificial implant loaded on the interventional delivery system, the artificial implant being an aortic valve with a first mark and comprising a stent and valve leaflets; the interventional delivery system comprises a catheter assembly, a control handle for controlling the catheter assembly, and an interception device connected to the control handle, the interception device being a filter for capturing blood clots or a deflection device for guiding blood clots, wherein the delivery channels of the interception device and the artificial implant are independently configured with pipe fittings or utilize a multi-lumen tube structure; the interventional delivery system has a third mark, and when the artificial implant is loaded on the interventional delivery system, the circumferential relative position between the first mark and the third mark is adjusted based on deviation information, wherein the deviation information is obtained by comparing the position information of each sinus of a native aortic valve with reference information. The interventional system with interception function can effectively deflect and capture blood clots and the like generated in the body, thereby reducing the risk.

The utility model discloses a kind of delivery sheaths, it is related to medical instrument technical field, including sheath tube, sheath tube has sheath tube distal end first curved section, sheath tube distal end second curved section, sheath tube distal end third curved section and sheath tube main body section in turn from the distal end of sheath tube to the proximal end of sheath tube on sheath tube, the center line of sheath tube distal end first curved section and the center line of sheath tube distal end second curved section are on first plane, the center line of sheath tube distal end third curved section and the center line of sheath tube main body section are on second plane, the included angle between second plane and first plane is greater than 0 and less than 90 °;The center line of sheath tube distal end third curved section can be parallel with the center line of aortic arch, the outlet on sheath tube distal end first curved section can be directly opposite aortic valve orifice;The utility model can effectively avoid blood vessel or valve injury.

The present invention relates to compounds, pharmaceutical compositions, combination preparations, and dosage guidelines for the treatment, inhibition of progression, and prevention of cardiovascular calcification, and in particular, coronary calcification, aortic artery calcification, and aortic valve calcification, comprising inositol phosphates. In one particular aspect, the disclosure provides a dosage guideline for the treatment, inhibition of progression, or prevention of cardiovascular calcification comprising the administration of approximately 200 mg to approximately 700 mg of myo-inositol hexaphosphate per dose.

The invention relates to an aortic valve related event risk prediction method and system based on multi-time-point data, and the method comprises the following steps: collecting multi-time-point baseline data parameters and longitudinal follow-up visit data of a patient, carrying out the preprocessing, and extracting related features; constructing a medical constraint matrix based on the related features, and calculating a time attenuation weight matrix; carrying out medical constraint guided feature screening by adopting an improved random forest algorithm, carrying out layered constraint feature sampling based on a medical constraint matrix and a time decay weight matrix when nodes of each decision tree are constructed, and selecting key features from related features through iteration; calculating a fusion weight based on the time attenuation weight matrix, the medical constraint matrix and the feature reliability; and performing weighted fusion on the key features based on the fusion weight to obtain an aortic valve related event risk prediction result. Compared with the prior art, the aortic valve related event risk prediction method can integrate multi-time-point and multi-modal data, and has the advantages of accurate aortic valve related event risk prediction and the like.

The invention belongs to the technical field of medicine, and particularly relates to application of glycin in preparation of medicine for treating aortic valve calcification, micro-nano particles and a preparation method of the micro-nano particles, the micro-nano particles are of a core-shell structure, the core of the micro-nano particles is a glycin-loaded gel microsphere formed by hyaluronic acid methylacrylate through photo-crosslinking, and the core of the micro-nano particles is a chitosan microsphere formed by hyaluronic acid methylacrylate through photo-crosslinking. The shell covers the outside of the core and is formed by crosslinking calcium alginate ions; the particle size of the micro-nano particles is 90 to 110 [mu] m. According to the preparation method disclosed by the invention, a micro-fluidic chip technology is mainly adopted, and photo-crosslinking and ionic crosslinking are combined, so that the finally obtained GG-HAMA at SA has the characteristic of antagonizing aortic valve calcification.

The application relates to the field of biological medicines, and particularly discloses application of aigilCES carbon dots in preparation of a drug for treating aortic valve calcification disease. The aigilCES carbon dots are prepared from aigilCES leaf powder as raw material, through ultrasonic extraction with an organic solvent, concentration, hydrothermal reaction at 140 DEG C to 180 DEG C for 4 h to 10 h, and then purification, and the particle size is 2.3+ / -0.4 nm. The aigilCES carbon dots provided by the application can significantly inhibit the formation of calcified nodules, are suitable for an aortic valve calcification pathological model induced by beta-glyceryl sodium phosphate, ascorbic acid and dexamethasone, and provide a new way for relieving the symptoms of aortic valve calcification disease.

The application provides a left ventricular end-diastolic pressure calculation method, device, computer equipment and storage medium, comprising: collecting the current and outlet pressure value of a catheter pump, obtaining a heart beat cycle, an inlet pressure value, an aortic valve opening time and an aortic valve closing time; determining a heart diastolic time according to the heart beat cycle, the aortic valve opening time and the aortic valve closing time; determining a current diastolic pressure value according to the outlet pressure value; determining a left ventricular pressure minimum value according to the inlet pressure value; determining an isovolumic relaxation time constant according to the inlet pressure value and the aortic valve closing time; determining an isovolumic contraction efficiency according to the inlet pressure value and the aortic valve opening time; and calculating the left ventricular end-diastolic pressure based on the heart diastolic time, the current diastolic pressure value, the left ventricular pressure minimum value, the isovolumic relaxation time constant and the isovolumic contraction efficiency. The above method can safely and accurately predict the left ventricular end-diastolic pressure.